Then, this is the segment with the strongest focus in Pfizer's pipeline. If we take a look at the top 10 products in 2023, the ranking is still led by Comirnaty (19% weight), despite the drop in ...
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...
Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor. After a thorough ...
Hosted on MSN1mon
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?Unfortunately, the main patent protecting its market ... In addition to a heap of new products like Padcev pushing up revenue, Pfizer is shrinking the size of its operation. In 2024, the company ...
Pfizer (NYSE: PFE) became a stock market star in early pandemic days as it brought the first coronavirus vaccine to market.
Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...
led to significant growth for the company -- followed by decline when demand for the products waned. At the same time, the expiration of key patents is coming up for some major Pfizer drugs ...
Pfizer's Bladder Cancer Therapy Meets Main Goal in Late-Stage Study (Reuters) -Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained ...
(Reuters) -Pfizer's experimental treatment for a type ... in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study in patients with high-risk non-muscle invasive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback